



INTERNATIONAL GENERIC AND
BIOSIMILAR MEDICINES ASSOCIATION

FOR IMMEDIATE RELEASE

Contact: David Gaugh igba@igbamedicines.org

IGBA CONGRATULATES THE AUSTRALIAN GOVERNMENT FOR MAINTAINING THEIR BIOLOGICS NAMING CONVENTION AND FOR STRENGTHENING PHARMACOVIGILANCE

The International Generic and Biosimilar medicines Association (IGBA) welcomes the Australian Government's decision to maintain the existing naming convention for biological, including biosimilar, medicines, that is to continue using the Australian biological name (without a specific identifier suffix) and to strengthen the adverse event reporting. This includes making the product's trade name, as well as the non-proprietary name, a mandatory field when reporting an adverse event to the Therapeutic Goods Administration (TGA).

This Government's decision aligns with the EU, which has approved the highest number of biosimilar medicines worldwide, and has acquired considerable experience of their use and safety.¹ Indeed, "over the last 10 years, the EU monitoring system for safety concerns has not identified any difference in the nature, severity or frequency of adverse effects between biosimilars and their reference medicine"². Furthermore, the preliminary results of an ongoing European Medicines Agency's (EMA) pharmacovigilance study showed that 95,5% overall product identification has been achieved for classes of biologicals for which biosimilar medicines have been approved.³

The Australian Government's decision also aligns with the World Health Organization's (WHO) approach for nomenclature of Biological Medicines.

IGBA also applauds this decision as it supports quality use of medicines, including safe prescribing and dispensing practice, by avoiding the complexity and potential confusion that would be associated with the introduction of a non-memorable suffix-based system.

- ¹ [Biosimilar Medicines Clinical Use: An Experience Based-EU Perspective](#)
- ² [EMA – European Commission: Biosimilars in the EU – Information guide for healthcare professionals, 2017 \(link\)](#)
- ³ [A Clinician's Guide to Biosimilars in Oncology: Understanding the Science of Extrapolation and Interchangeability – Dr. Elena Wolff-Holz](#)



Association for Accessible Medicines
601 New Jersey Ave
NW, Suite 850
Washington DC 20001
T: +1 202 249 7100
accessiblemeds.org



Canadian Generic Pharmaceutical Association
4120 Yonge Street
Suite 409
Toronto, Ontario
M2P 2B8, Canada
T: +1 416 223 2333
canadiangenerics.ca



Generic & Biosimilar Medicines Southern Africa
1342 Howick Mews,
Waterfall Park,
Bekker Rd, Midrand
Box 32361, Kyalami, 1684
T: +27 11 312 6966
gbmsa.org



Indian Pharmaceutical Alliance
A-205 Sangam,
14B S V Road,
Santacruz West,
Mumbai 400054.
T: +91-22-2610 9281
ipa-india.org



Jordanian Association of Pharmaceutical Manufacturers
Khalda, Villa No. 1
Yazan Aranki St.
P.O. Box 5382
Amman, 11953 Jordan
T: +962 6 5413114
japm.com



Japan Generic Medicines Association
3-3-4 Nihonbashi-honcho
Chuo-ku, Tokyo
103-0023 Japan
T: +81 3 3279 1890
jga.gr.jp



Medicines for Europe
Rue d'Arlon 50
B-1000 Brussels,
Belgium
T: +32 2 736 84 11
medicinesforeurope.com



Taiwan Generic Pharmaceutical Association
Fl. 5, No. 32-1,
Songjiang Rd.,
Taipei City 104,
Taiwan
T: +886 02-25314389
tgpa.org.tw



Mexican Association of Generic Medicines
Viaducto Miguel Alemán
No. 193-2
Col. Escandón
C.P. 11800 - México,
D.F.
T: +52 5273-7708
amegi.com.mx



Generic and Biosimilar Medicines Association
PO Box 87
Deakin West ACT 2600
gbma.com.au



Malaysian Organisation of Pharmaceutical Industries
Global Business &
Convention Centre
Mezzanine floor, block a,
No. 8, Jalan 19/1, section
19, 46300 Petaling Jaya
Selangor Darul Ehsan –
Malaysia
T: +603-7931 9003
mopi.org.my



Brazilian Generic Medicine Drugmakers Association
Rua Alvorada, 1280
CEP : 04550-004
São Paulo – SP
T: +55 (11) 3897-9767
progenericos.org.br



INTERNATIONAL GENERIC AND
BIOSIMILAR MEDICINES ASSOCIATION

About IGBA

The International Generic and Biosimilar Medicines Association (IGBA) was founded as IGPA (International Generic Pharmaceutical Alliance) in March 1997 to strengthen cooperation between associations representing manufacturers of generic medicines from around the world. Its membership includes AAM (USA), CGPA (Canada), GBM – Southern Africa (South Africa), IPA (India), JAPM (Jordan), JGA (Japan), Medicines for Europe (Europe), and TGPA (Taiwan), while the associations from Australia (GBMA), Brazil (ProGenericos), Mexico (AMEGI), and Malaysia (MOPI) are Associate Members. The IGBA is at the forefront of preserving sustainable competition within our industry, by stimulating competitiveness and innovation in the pharmaceutical sector; thereby, ensuring millions of patients around the world have access to high quality, pro-competitive medicines. Through its constituent member associations, the IGBA maintains constant dialogue with government authorities around the world, as well as with international institutions such as WTO, WIPO and WHO. More information: www.igbamedicines.org